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skin cancerArsenic-contaminated drinking water presents a serious health hazard in certain geographic locations
around the world. Chromated copper arsenate, a pesticide and preservative that was used to pressure
treat residential lumber in the United States beginning in the 1940s andwas banned by the Environmental
Protection Agency in 2003, poses a potential source of arsenic exposure and toxicity. In this study, we re-
view the clinicalmanifestations of arsenic intoxicationwith the focus on dermatologicmanifestations. Der-
matologists should be aware that although chromated copper arsenate-treated wood for residential use
was banned in 2003, the exposure risk remains. Long-term follow up is necessary to detect arsenic induced
cutaneous and visceral malignancy in patients with history of arsenic exposure.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Arsenic is a naturally occurring heavy metal substance. It is rarely
found in its pure elemental state; rather combining with various ele-
ments to form inorganic and organic arsenic. Inorganic arsenic com-
pounds are more toxic than organic arsenic compounds (Jomova
et al., 2011; Schuhmacher-Wolz et al., 2009). Inorganic arsenic was
designated a human carcinogen by theU.S. Environmental Protection
Agency (EPA) in 1986 (Levine et al., 1988).
Arsenic has beenused both as a therapeutic agent inmedicine and
as a poison for more than 2,000 years. Arsenic preparations were
used in the 18th and 19th centuries as antipyretics, antiseptics, caus-
tics, antispasmodics, depilatories, sedatives, tonics, and as an agent to
combat trypanosomiasis (Haller, 1975; Waxman and Anderson,
2001). In the 1700s, Thomas Fowler developed a 1% solution of arse-
nic trioxide in potassium bicarbonate that was used empirically for
the treatment of dermatologic diseases such as dermatitis, pemphi-
gus, and psoriasis. Fowler’s solution also was used to treat asthma
and chorea (Aronson, 1994; Kwong and Todd, 1997).
The effect of Fowler’s solution on leukocytes was noted after a pa-
tient with chronic myelogeneous leukemia was found to have a dra-
matic decline of white blood cells when treated with Fowler’s, University of Connecticut
6019. Tel.: +860 679 4600;
on behalf of Women's Dermatologsolution (Cutler and Bradford, 1878). In 2000, the Food and Drug Ad-
ministration approved arsenic trioxide infusion for induction of re-
mission and consolidation in patients with acute promyelocytic
leukemia who were refractory to, or had relapsed from, retinoid
and anthracycline chemotherapy, and whose leukemia had yielded
the presence of the t(15;17) translocation or PML/RAR-α gene expres-
sion (Trisenox, 2000).
Environmental exposure to arsenic can either be due to natural
occurrence (air, soil, water) or as a result of anthropogenic activities.
The largest source of environmental exposure to arsenic is dietary,
such as seafood and poultry. Fortunately, arsenic compounds found
in these sources are essentially harmless in the form of organic arse-
nic (Jomova et al., 2011). In contrast, millions of people in
Bangladesh, India, Taiwan, China, southeast Asia, and North and
South America are exposed to inorganic arsenic via drinking water
due to high concentrations from geogenic sources (Berg et al., 2001;
Tapio and Grosche, 2006). Recently, traditional Chinese and Tibetan
herbal products, fortiﬁed with arsenic for its therapeutic purposes,
have been found to present a serious health hazard (Martena et al.,
2010; Wong et al., 1998).
Exposure to arsenic and its various compounds has well-
documented detrimental effects on human health. Inorganic arsenic
is far more toxic than organic arsenic due to generation of free radi-
cals and oxidative stress resulting in cellular damage and cell death
(De Vizcaya-Ruiz et al., 2009; Shi et al., 2004). Furthermore, it alters
DNA repair and methylation patterns, resulting in enhanced cellic Society. This is an open access article under the CC BY-NC-ND license
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et al., 2011; Kitchin, 2001; Schuhmacher-Wolz et al., 2009).
Manifestations of arsenic toxicity depend on the dose, route, age
at exposure, and duration of exposure. Measurements of arsenic
level in blood, urine, hair, and nails have been used as indicators for
exposure (Jomova et al., 2011). Testing for and interpreting results
of arsenic levels can be complicated. Therefore, direct communication
with the testing laboratory and consultationwith a toxicologist is rec-
ommended. Blood levels are usually not a reliablemarker because ar-
senic is metabolized rapidly (Tam et al., 1979). Both organic and
inorganic arsenic are excreted by the kidney and quantiﬁcation as
well as speciation of the urinary arsenic is reliable for the diagnosis
of acute and chronic arsenicism (Goldman, 2016; Jomova et al.,
2011). Total urine arsenic level is generally less than 10 μg/g creati-
nine in individuals without occupational arsenic exposure and who
have not consumed ﬁsh, as a single meal of ﬁsh can increase total
urine arsenic to more than 1,000 μg/L.
In an emergent situation suspicious for acute arsenic intoxication,
a spot urine arsenic can be obtained. However, urine creatinine in
the spot sample must also be obtained to correct for the urine con-
centration. A diagnosis of acute arsenic exposure is supported when
urine arsenic concentration is greater than or equal to 50 μg/L, or
100 μg/g creatinine in the absence of recent ﬁsh intake. A 24-hour
urine arsenic is a more accurate measurement than a spot urine
arsenic to assess for chronic arsenic exposure. It is important to re-
mind patients to avoid ﬁsh for 48 to 72 hours before sample collec-
tion. As discussed previously, urine arsenic typically is less than
10 μg/g creatinine in individuals without occupational or dietary ar-
senic exposure (Goldman, 2016). Hair and nail arsenic levels are
used to document chronic exposure (Chen et al., 2005a). However,
variable results often are reported due to lack of standardized testing
(Goldman, 2016).
Although rarely mentioned, dermatologic manifestations can be
present in acute arsenic toxicity. In one study, it was noted that 56%
of acute arsenic poisoning victims exhibited dermatologic ﬁndings
such as, in decreasing order of frequency, conjunctival hemorrhage,
facial edema, acral desquamation, maculopapular eruptions in
intertriginous areas, and transient ﬂushing (Uede and Furukawa,
2003). Dermatologic ﬁndings of chronic arsenic exposure such as
Mee’s line of the nail, palmar-plantar hyperkeratosis, and focal or
generalized raindrop hyperpigmentation in sun-protected areas
have been well documented (Wong et al., 1998). Interestingly, mac-
ular hypopigmentation was noted in studies from Asia (Miki et al.,
1982; Wong et al., 1998).
The most common arsenic-induced skin cancers include Bowen’s
disease (BD), basal cell carcinoma (BCC), and squamous cell carcino-
ma (SCC). Results from a case–control study found that in individuals
with toenail arsenic concentrations above the 97th percentile, the ad-
justed ratios for SCC and BCC were 2.07 (95% conﬁdence interval [CI]
[0.92, 4.66]) and 1.44 (95% CI [0.74, 2.81]) respectively, when com-
pared with those at or below the median concentration (Karagas
et al., 2001). Clinical characteristics suggestive of arsenic-induced
skin cancer include occurrence on sun-protected areas as well as
multiple and recrudescent lesions (Yu et al., 2001). Identiﬁcation of
palmar-plantar keratosis and BD should raise the suspicion of chronic
arsenicism (Allen et al., 1979). The latency period for the develop-
ment of arsenical keratosis, BD, BCC, and SCC ranges from 15 to 40
years, which underscores the importance of long-term follow up
(Wong et al., 1998).
The occurrence of arsenic-induced skin cancer in sun-protected
areas is of particular interest. One study found decreased number of
Ki 67-positive cells in arsenic-induced BD 2 weeks after ultraviolet
B (UVB) irradiation when compared with nonirradiated skin of the
same individual. The authors postulate a UVB inhibitory effect on
arsenic-induced cell proliferation as a potential explanation forﬁnding skin cancer in sun-protected areas in arsenic exposed individ-
uals (Chai et al., 1997). However, arsenic andUV radiation are known
co-carcinogens in animal models (Burns et al., 2004). More recently,
it was found that pretreatment of normal human cultured
keratinocytes in vitro with arsenic prevents these keratinocytes
from undergoing UVA- and UVB-induced apoptosis (Chen et al.,
2005b; Sun et al., 2011). It is likely that different molecular signals
are activated by arsenic, UVA, and UVB resulting in a complex inter-
play between them in vivo. For example, a study of p53 mutations
in arsenic-related skin cancers found a higher rate and different
types of p53 mutations when compared with those in UV-induced
skin cancer (Hsu et al., 1999). Langerhans cell dysfunction and chang-
es in the cytokine milieu further complicate this already complex re-
lationship (Wang et al., 1991; Yu et al., 1992a; Yu et al., 1992b).
Although melanoma has not been historically associated with ar-
senic exposure, a case–control study showed an increased risk for
melanoma in individuals with elevated toenail arsenic (odds
ratio = 2.1, 95% CI [1.4, 3.3]) (Beane Freeman et al., 2004). However,
inorganic arsenic compounds inhibit cell proliferation and prevent
invasion of human and murine melanoma cell lines in vitro
(Hiwatashi et al., 2011). Furthermore, arsenic trioxide has been dem-
onstrated to induce a mitochondrial dependent apoptosis in human
uveal melanoma cells (Chen et al., 2010). The relationship between
arsenic and melanoma remains to be delineated.
In addition to the skin, virtually all organs can be affected by arse-
nic due to its effect on the vascular endothelium. Acute arsenic toxic-
ity may cause cardiomyopathy and hypotension, whereas chronic
arsenic toxicitymaymanifest as hypertension and ischemic heart dis-
ease (Mumford et al., 2007; Wang et al., 2003). Peripheral vascular
disease as well as cerebral infarct also are noted. Gastrointestinal
symptoms such as nausea, vomiting, diarrhea, abdominal pain, and
hematemesis are observed in short-term high-dose and long-term
low-dose exposure (Jomova et al., 2011). Elevated liver enzymes
with portal ﬁbrosis, cirrhosis, and bronchiectasis can be observed
(Liu et al., 2002; Mazumder et al., 2005; Rahman et al., 2009). The
most typical neurologic manifestation is symmetrical peripheral sen-
sory andmotor neuropathy, whichmay last for years and is only par-
tially reversible (Fincher and Koerker, 1987; Mathew et al., 2010).
Based on epidemiologic studies, visceral malignancies involving the
lung, bladder, kidney, liver, colon, and bone have been associated
with arsenic exposure in a dose–response relationship after a long la-
tency period (Enterline et al., 1995; Gibb et al., 2011).
Management of both acute and chronic arsenic exposure remains
supportive and symptomdirected. There is no antidote for arsenic in-
toxication. Two chelation therapies are available in the United States.
Dimercaprol, also known as British Anti-Lewisite, is the chelating
drug of choice for acute severe arsenic toxicity. Although few data
supports the use of chelation therapy in subacute or chronic arsenic
poisoning, meso-2, 3-dimercaptosuccinic acid is the preferred agent
in the setting of ongoing arsenic exposure. In both acute and chronic
arsenic exposure, it is paramount to eliminate further exposure and
contamination (Goldman, 2016).
Chromated copper arsenate (CCA), which contains 47.5%
hexavalent chromium, 18.5% copper, and 34% inorganic arsenic, is a
pesticide and preservative that was used to pressure treat lumber be-
ginning in the 1940s. In the 1970s, CCAwaswidely used in theUnited
States for outdoor residential wood such as decks, picnic tables, land-
scaping timbers, fencing, patios, walkways, boardwalks, and play-
ground structures until it was phased out by the EPA in 2003. The
history and regulatory events leading to the phasing out of the CCA-
treated residential wood product is complicated and beyond the
scope of the current discussion. In brief, similar to all other pesticides,
CCA is registered under the Federal Insecticide, Fungicide and Roden-
ticide Act by the EPA. In 2001, the EPA and U.S. Consumer Product
Safety Commission received public petitions to ban CCA use in
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contacting this chemical residue from the treated wood and sur-
rounding soil (U.S. Consumer Product Safety Commission, 2011). As
a result, in February 2002, the manufacturers of CCA voluntarily
amended their registrations, requesting the EPA to terminate resi-
dential uses of CCA products and canceling their registrations (U.S.
Environmental Protection Agency, 2003).
Cancellation of these registrations went into effect in March 2003
(U.S. Environmental Protection Agency, 2003). Although no manu-
facturer has been able to treat wood with CCA for residential uses
since December 2003, the EPA does not prohibit the sale of CCA-
treated wood produced before 2003. However, retailers must display
a warning label when CCA-treated wood is sold. The Consumer
Awareness Program also recommends wearing gloves when han-
dling wood, wearing goggles and masks when sawing and sanding,
and never burning CCA-treated wood. Acute and chronic arsenicism
have been reported with burning CCA-treated wood (Peters et al.,
1983, 1984, 1986).
It is important to remember that alongwith contaminated ground
water and Fowler’s solution, CCA-treated wood is a source of signiﬁ-
cant arsenic exposure. Dermatologists should be aware that although
CCA-treated wood for residential use was banned in 2003, exposure
risk remains, especially as airborne particulates have been found at
incendiary or construction sites. Long-term follow up is necessary
to detect arsenic-induced cutaneous and visceral malignancy in pa-
tients with history of arsenic exposure.
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